Intelligence for the Dealmaking Community since 1965
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
This is premium content

To read the full story, please upgrade your plan.

Upgrade plan
Login to your account

Novartis

deals of the year
Honors
Mergers & Acquisitions Reveals the 2024 Middle-Market Deals of the Year
This marks our 17th year naming its top deals. Our editors identified 11 transactions that transcended market headwinds faced by dealmakers.
May 6, 2024
deals of the year
Healthcare
Mergers & Acquisitions 2024 Deals of the Year: Novartis Acquired DTx Pharma
The acquisition reinforced that biopharma companies using RNA platforms will be highly sought after by potential acquirers.
May 6, 2024
image
Healthcare
BPOC Joins PE Push Into Clinical Trial Sites
Private equity firms are creating clinical trial platforms to roll up independents in a highly fragmented industry.
January 9, 2024
image
Healthcare
Biotech Milestones: Almost Always Included, Almost Never Hit
Most biopharma deals are for companies without any products on the market, which require FDA approval after costly and time-consuming clinical trials.
November 10, 2023

Trending

1.
Secondaries Edge: Smaller Sponsors, Sovereign Sellers and Tougher Standards
July 22, 2026
2.
Inside the Lower Middle Market’s Two-Track Deal Sourcing Strategy
July 20, 2026
3.
Partners Group Raises $15B Fourth Direct Infra Fund
July 20, 2026
4.
Secondaries Edge: Liquidity, Conflicts and the Fine Print
August 5, 2026
5.
Private Credit Has the Cash, Now It Needs the Deals
July 21, 2026
6.
GTCR Closes $1.25B Inaugural Capital Solutions Fund
July 29, 2026
7.
Mid-Market M&A Takes a Summer Break
August 6, 2026
8.
Distressed Credit’s New Pitch: Protection Before Upside
July 17, 2026
9.
Francisco Partners Closes $21B Across Flagship and Mid-Market Funds
July 23, 2026